Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. Academic Article uri icon

Overview

abstract

  • In this study we determined the influence of cholinergic up-regulation by rivastigmine, an acetylcholinesterase inhibitor, on central nervous system inflammation. Neuroinflammation was induced in experimental autoimmune encephalomyelitis (EAE). Rivastigmine markedly ameliorated clinical symptoms of EAE and the spatial memory deficits induced by EAE. It also reduced demyelination, microglia activation and axonal damage. Rivastigmine decreased the reactivity of encephalitogenic T-cells and the production of pro-inflammatory cytokines (TNF-alpha, IFN-gamma and IL-17) without affecting IL-10 production. These effects were abolished by alpha7 nicotinic acetylcholine receptor antagonists. Antigen presentation was also affected by this treatment. Thus, rivastigmine treatment had immunomodulatory activity in EAE.

publication date

  • October 15, 2008

Research

keywords

  • Cholinesterase Inhibitors
  • Encephalomyelitis, Autoimmune, Experimental
  • Immunosuppressive Agents
  • Phenylcarbamates

Identity

Scopus Document Identifier

  • 53149137393

Digital Object Identifier (DOI)

  • 10.1016/j.jneuroim.2008.06.018

PubMed ID

  • 18692909

Additional Document Info

volume

  • 203

issue

  • 1